2018
DOI: 10.1002/jso.24998
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The TSR confirmed to be a strong prognosticator for disease-free survival in a selected high-risk patient population. No benefit was found in response to treatment with bevacizumab when stratified for TSR. TSR showed to have an additional prognostic value in patients with vascular invasion present in the primary tumor.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
7
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 11 publications
(8 citation statements)
references
References 18 publications
1
7
0
Order By: Relevance
“…Low microenvironment cytotoxic lymphocyte counts associates with higher chances of disease recurrence or death, particularly when tumors have a stromal invasive phenotype infiltrated with CAFs. Our results are in line with extensive literature built on pathology assessments of the tumor microenvironment showing the protective role of high infiltration by CD8+ cytotoxic T cells (approximately one-third of early-stage CRC population) [8] and the unfavorable outcome of patients whose tumors harbor high infiltration with stromal fibroblasts (∼40% of early-stage CRC population) [21]. Our data also suggest that the worse outcomes repeatedly seen in patients whose tumors display a mesenchymal-like phenotype may be directly linked to a prometastatic immune evasive and stromal-rich microenvironment.…”
Section: Discussionsupporting
confidence: 88%
“…Low microenvironment cytotoxic lymphocyte counts associates with higher chances of disease recurrence or death, particularly when tumors have a stromal invasive phenotype infiltrated with CAFs. Our results are in line with extensive literature built on pathology assessments of the tumor microenvironment showing the protective role of high infiltration by CD8+ cytotoxic T cells (approximately one-third of early-stage CRC population) [8] and the unfavorable outcome of patients whose tumors harbor high infiltration with stromal fibroblasts (∼40% of early-stage CRC population) [21]. Our data also suggest that the worse outcomes repeatedly seen in patients whose tumors display a mesenchymal-like phenotype may be directly linked to a prometastatic immune evasive and stromal-rich microenvironment.…”
Section: Discussionsupporting
confidence: 88%
“…One method by which the tumour microenvironment can be measured is via the proportion of epithelial tumour tissue vs stroma in tumour-tissue sections. The tumour-stroma percentage has been confirmed as a prognostic factor in CRC studies in stage II and III CRC patients from the VICTOR trial, with OS and DFS being significantly lower in patients with a high percentage of tumour stroma (>50%) with 5-year OS and DFS for stroma-high vs stroma-low patients of 69.0% vs. 83.4% and 58.6% vs. 77.3%, respectively [62]. The use of such parameters in combination with current pathological assessments could provide a low-cost addition to the TNM status and, for example, MSI status.…”
Section: Tools Available For Predicting Chemotherapy Benefitsmentioning
confidence: 99%
“…The tumour stroma and the microenvironment promote angiogenesis and tumour progression and eventually metastasis [10, 20]. There is increasing evidence that the proportion of this stroma in colon cancer is inversely related to survival [21, 22]. Consequently, tumours with high tumour-stroma percentage (TSP) are likely to express more angiogenic factors, leading to more angiogenesis, and angiogenesis-rich tumours may be associated with a worse prognosis.…”
Section: Introductionmentioning
confidence: 99%